Compare ACRS & PDM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ACRS | PDM |
|---|---|---|
| Founded | 2012 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Building operators |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 868.5M | 1.0B |
| IPO Year | 2015 | 1997 |
| Metric | ACRS | PDM |
|---|---|---|
| Price | $6.28 | $9.77 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 2 |
| Target Price | ★ $10.20 | $9.00 |
| AVG Volume (30 Days) | ★ 1.9M | 826.6K |
| Earning Date | 05-07-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 69.01 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $1,683,000.00 | ★ $564,994,000.00 |
| Revenue This Year | N/A | $4.21 |
| Revenue Next Year | $4.24 | $1.29 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.74 | $6.32 |
| 52 Week High | $6.52 | $10.13 |
| Indicator | ACRS | PDM |
|---|---|---|
| Relative Strength Index (RSI) | 61.76 | 56.94 |
| Support Level | $4.13 | $9.23 |
| Resistance Level | $6.52 | $9.97 |
| Average True Range (ATR) | 0.36 | 0.24 |
| MACD | 0.03 | -0.01 |
| Stochastic Oscillator | 83.72 | 78.88 |
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company. It focuses on developing novel drug candidates for immuno-inflammatory diseases using its proprietary KINect drug discovery platform. The company's pipeline consists of the following key product candidates: Bosakitug (ATI-045), an investigational, novel, humanized anti-TSLP monoclonal antibody being developed for patients with severe asthma, COPD, and chronic rhinosinusitis with nasal polyps; ATI-2138, being developed for the potential treatment of T cell-mediated autoimmune diseases; and ATI-052 and ATI-9494. Additionally, it has an investigational product candidate, Lepzacitinib (ATI-1777), which is being focused upon as a potential treatment for atopic dermatitis and potentially other dermatologic conditions.
Piedmont Realty Trust Inc is a fully integrated, self-managed real estate investment company focused on delivering an exceptional office environment. As an owner, manager, developer and operator of 16 MM SF of Class A properties across U.S. Sunbelt markets, Piedmont Realty Trust is known for its hospitality-driven approach and commitment to transforming buildings into Piedmont PLACEs that enhance each client's workplace experience.